Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure.
During peritoneal dialysis (PD), the peritoneum is exposed to bioincompatible dialysis fluids, which causes progressive fibrosis and angiogenesis and, ultimately, ultrafiltration failure. In addition, repeated episodes of peritonitis or hemoperitoneum may accelerate all these processes. Fibrosis has been classically considered the main cause of peritoneal membrane functional decline. However, in parallel with fibrosis, the peritoneum also displays increases in capillary number (angiogenesis) and vasculopathy in response to PD. Nowadays, there is emerging evidence pointing to peritoneal microvasculature as the main factor responsible for increased solute transport and ultrafiltration failure. However, the pathophysiologic mechanism(s) involved in starting and maintaining peritoneal fibrosis and angiogenesis remain(s) elusive. Peritoneal stromal fibroblasts have been considered (for many years) the cell type mainly involved in structural and functional alterations of the peritoneum; whereas mesothelial cells have been considered mere victims of peritoneal injury caused by PD. Recently, ex vivo cultures of effluent-derived mesothelial cells, in conjunction with immunohistochemical analysis of peritoneal biopsies from PD patients, have identified mesothelial cells as culprits, at least in part, in peritoneal membrane deterioration. This review discusses recent findings that suggest new peritoneal myofibroblastic cells may arise from local conversion of mesothelial cells by epithelial-to-mesenchymal transition during the repair responses that take place in PD. The transdifferentiated mesothelial cells may retain a permanent mesenchymal state, as long as initiating stimuli persist, and contribute to PD-induced fibrosis and angiogenesis, and hence to membrane failure. Future therapeutic interventions could be designated in order to prevent or reverse epithelial-to-mesenchymal transition of mesothelial cells, or its pernicious effects.
López-Cabrera
Manuel
M
Unidad de Biología Molecular, Hospital Universitario de la Princesa, Diego de León, 62, 28006 Madrid, Spain. mlopez.hlpr@salud.madrid.org
Aguilera
Abelardo
A
Aroeira
Luiz S
LS
Ramírez-Huesca
Marta
M
Pérez-Lozano
M Luisa
ML
Jiménez-Heffernan
José A
JA
Bajo
M Auxiliadora
MA
del Peso
Gloria
G
Sánchez-Tomero
José A
JA
Selgas
Rafael
R
D001692:Biological Transport; D002478:Cells, Cultured; D015314:Dialysis Solutions / Q000493:pharmacokinetics; D004847:Epithelial Cells; D005355:Fibrosis / Q000209:etiology / Q000473:pathology; D006801:Humans; D009389:Neovascularization, Pathologic / Q000209:etiology / Q000473:pathology; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010537:Peritoneum / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology; D017211:Treatment Failure
D015314:Dialysis Solutions